Varian Medical Systems has received 510(k) clearance from the U.S. Food and Drug Administration for the latest version of its Eclipse proton therapy planning software.
Eclipse v16.1 includes the integration of dual-energy CT images from Siemens Healthineers CT scanners into the Eclipse planning process in order to reduce range uncertainties and help users preserve healthy tissue. Dual-energy imaging also provides more accurate information about tissue density, which enables dosimetrists to develop more precise treatment plans. The dual-energy feature was validated through a clinical collaboration with Roberts Proton Therapy Center at the University of Pennsylvania, according to Varian.
Another new feature in Eclipse v16.1 is the first clinical release of GPU Monte Carlo proton dose calculation technology. The feature was evaluated in partnership with the Emory Proton Therapy Center in Atlanta, and it helps clinicians to speed up calculation speed and improve overall treatment planning efficiency, Varian said.
